aTyr Pharma Statistics
Share Statistics
aTyr Pharma has 83.94M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 83.94M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 957 |
| FTD / Avg. Volume | 0.09% |
Short Selling Information
The latest short interest is 2.92M, so 3.48% of the outstanding shares have been sold short.
| Short Interest | 2.92M |
| Short % of Shares Out | 3.48% |
| Short % of Float | 3.56% |
| Short Ratio (days to cover) | 3.71 |
Valuation Ratios
The PE ratio is -1.84 and the forward PE ratio is -4.42.
| PE Ratio | -1.84 |
| Forward PE | -4.42 |
| PS Ratio | 262.72 |
| Forward PS | 5.2 |
| PB Ratio | 1.02 |
| P/FCF Ratio | -2.48 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for aTyr Pharma Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.27, with a Debt / Equity ratio of 0.
| Current Ratio | 6.27 |
| Quick Ratio | 6.27 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.56% and return on capital (ROIC) is -52.02%.
| Return on Equity (ROE) | -0.56% |
| Return on Assets (ROA) | -0.42% |
| Return on Capital (ROIC) | -52.02% |
| Revenue Per Employee | 6.30K |
| Profits Per Employee | -899.80K |
| Employee Count | 56 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 1.1, so aTyr Pharma 's price volatility has been higher than the market average.
| Beta | 1.1 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 3.29 |
| 200-Day Moving Average | null |
| Relative Strength Index (RSI) | 68.26 |
| Average Volume (20 Days) | 1.09M |
Income Statement
In the last 12 months, aTyr Pharma had revenue of 353.00K and earned -50.39M in profits. Earnings per share was -0.94.
| Revenue | 353.00K |
| Gross Profit | -2.39M |
| Operating Income | -54.92M |
| Net Income | -50.39M |
| EBITDA | -52.18M |
| EBIT | -54.92M |
| Earnings Per Share (EPS) | -0.94 |
Balance Sheet
The company has 22.54M in cash and 15.10M in debt, giving a net cash position of 7.45M.
| Cash & Cash Equivalents | 22.54M |
| Total Debt | 15.10M |
| Net Cash | 7.45M |
| Retained Earnings | -468.02M |
| Total Assets | 91.62M |
| Working Capital | 62.20M |
Cash Flow
In the last 12 months, operating cash flow was -33.22M and capital expenditures -4.21M, giving a free cash flow of -37.44M.
| Operating Cash Flow | -33.22M |
| Capital Expenditures | -4.21M |
| Free Cash Flow | -37.44M |
| FCF Per Share | -0.7 |
Margins
Gross margin is -67.65K%, with operating and profit margins of -1.56M% and -1.43M%.
| Gross Margin | -67.65K% |
| Operating Margin | -1.56M% |
| Pretax Margin | -1.43M% |
| Profit Margin | -1.43M% |
| EBITDA Margin | -14.78K% |
| EBIT Margin | -15.56K% |
| FCF Margin | -10.61K% |
Dividends & Yields
ATYR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -23.62% |
| FCF Yield | -11.19% |
Analyst Forecast
The average price target for ATYR is $16, which is 302% higher than the current price. The consensus rating is "Buy".
| Price Target | $16 |
| Price Target Difference | 302% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Stock Splits
The last stock split was on Jul 1, 2019. It was a backward split with a ratio of 1:14.
| Last Split Date | Jul 1, 2019 |
| Split Type | backward |
| Split Ratio | 1:14 |
Scores
| Altman Z-Score | -3.03 |
| Piotroski F-Score | 1 |